Cargando…

Prospective assessment of the decision-making impact of the Breast Cancer Index in recommending extended adjuvant endocrine therapy for patients with early-stage ER-positive breast cancer

Extended adjuvant endocrine therapy (10 vs. 5 years) trials have demonstrated improved outcomes in early-stage estrogen receptor (ER)-positive breast cancer; however, the absolute benefit is modest, and toxicity and tolerability challenges remain. Predictive and prognostic information from genomic a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sanft, Tara, Aktas, Bilge, Schroeder, Brock, Bossuyt, Veerle, DiGiovanna, Michael, Abu-Khalaf, Maysa, Chung, Gina, Silber, Andrea, Hofstatter, Erin, Mougalian, Sarah, Epstein, Lianne, Hatzis, Christos, Schnabel, Cathy, Pusztai, Lajos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2015
Materias:	Clinical Trial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4661200/ https://www.ncbi.nlm.nih.gov/pubmed/26578401 http://dx.doi.org/10.1007/s10549-015-3631-9

Ejemplares similares

Mutation based treatment recommendations from next generation sequencing data: a comparison of web tools
por: Patel, Jaymin M., et al.
Publicado: (2016)

Multigene prognostic tests in breast cancer: past, present, future
por: Győrffy, Balázs, et al.
Publicado: (2015)

Uptake of exemestane chemoprevention in postmenopausal women at increased risk for breast cancer
por: Aktas, Bilge, et al.
Publicado: (2016)

Increased epigenetic age in normal breast tissue from luminal breast cancer patients
por: Hofstatter, Erin W., et al.
Publicado: (2018)

Persistence to extended adjuvant endocrine therapy following Breast Cancer Index (BCI) testing in women with early-stage hormone receptor-positive (HR +) breast cancer
por: Foldi, Julia, et al.
Publicado: (2023)

Cost-Effectiveness of Neoadjuvant-Adjuvant Treatment Strategies for Women With ERBB2 (HER2)–Positive Breast Cancer
por: Kunst, Natalia, et al.
Publicado: (2020)

Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy
por: Rozenblit, Mariya, et al.
Publicado: (2021)

Relevant factors for the optimal duration of extended endocrine therapy in early breast cancer
por: Blok, Erik J., et al.
Publicado: (2017)

Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone
por: Sestak, Ivana, et al.
Publicado: (2019)

Using Oncotype DX breast recurrence score® assay to define the role of neoadjuvant endocrine therapy in early-stage hormone receptor-positive breast cancer
por: Taylor, Caitlin, et al.
Publicado: (2023)

Discontinuation of adjuvant endocrine therapy and impact on quality of life and functional status in older patients with breast cancer
por: Lemij, Annelieke A., et al.
Publicado: (2022)

Limiting systemic endocrine overtreatment in postmenopausal breast cancer patients with an ultralow classification of the 70-gene signature
por: Opdam, M., et al.
Publicado: (2022)

A genome-wide approach to link genotype to clinical outcome by utilizing next generation sequencing and gene chip data of 6,697 breast cancer patients
por: Pongor, Lőrinc, et al.
Publicado: (2015)

Phase I trial to evaluate the addition of alisertib to fulvestrant in women with endocrine-resistant, ER+ metastatic breast cancer
por: Haddad, Tufia C., et al.
Publicado: (2017)

Plasma cell-free tumor DNA, PIK3CA and TP53 mutations predicted inferior endocrine-based treatment outcome in endocrine receptor-positive metastatic breast cancer
por: Chen, Tom Wei-Wu, et al.
Publicado: (2023)

Functional polymorphisms in cancer
por: Agarwal, Divyansh, et al.
Publicado: (2015)

Development of a Ki-67-based clinical trial assay for neoadjuvant endocrine therapy response monitoring in breast cancer
por: Goncalves, Rodrigo, et al.
Publicado: (2017)

Accuracy of breast MRI in patients receiving neoadjuvant endocrine therapy: comprehensive imaging analysis and correlation with clinical and pathological assessments
por: Reis, Joana, et al.
Publicado: (2020)

Evidence of accelerated epigenetic aging of breast tissues in patients with breast cancer is driven by CpGs associated with polycomb-related genes
por: Rozenblit, Mariya, et al.
Publicado: (2022)

Gene expression profiling of breast cancer
por: Pusztai, Lajos
Publicado: (2009)

Facilitating adherence to endocrine therapy in breast cancer: stability and predictive power of treatment expectations in a 2-year prospective study
por: Pan, Yiqi, et al.
Publicado: (2018)

Comparison of two targeted ultra-deep sequencing technologies for analysis of plasma circulating tumour DNA in endocrine-therapy-resistant breast cancer patients
por: Nteliopoulos, Georgios, et al.
Publicado: (2021)

Bridging pre-surgical endocrine therapy for breast cancer during the COVID-19 pandemic: outcomes from the B-MaP-C study
por: Dave, Rajiv V., et al.
Publicado: (2023)

Impact of a randomized weight loss trial on breast tissue markers in breast cancer survivors
por: Dieli-Conwright, Christina M., et al.
Publicado: (2022)

Phase III study of long-term prognosis of estrogen receptor-positive early breast cancer treated with neoadjuvant endocrine therapy with/without adjuvant chemotherapy
por: Iwata, Hiroji, et al.
Publicado: (2023)

Prognostic impact of adjuvant endocrine therapy for estrogen receptor-positive and HER2-negative T1a/bN0M0 breast cancer
por: Sasada, Shinsuke, et al.
Publicado: (2023)

AKT/mTOR signaling modulates resistance to endocrine therapy and CDK4/6 inhibition in metastatic breast cancers
por: Abu-Khalaf, Maysa M., et al.
Publicado: (2023)

Quantitative assessment of the spatial heterogeneity of tumor-infiltrating lymphocytes in breast cancer
por: Mani, Nikita L., et al.
Publicado: (2016)

Preventing metastatic recurrence in low-risk ER/PR + breast cancer patients—a retrospective clinical study exploring the evolving challenge of persistence with adjuvant endocrine therapy
por: Kuhn, Elaine P., et al.
Publicado: (2023)

Characterization of DNA variants in the human kinome in breast cancer
por: Agarwal, Divyansh, et al.
Publicado: (2015)

Tumor-Specific Major Histocompatibility-II Expression Predicts Benefit to Anti–PD-1/L1 Therapy in Patients With HER2-Negative Primary Breast Cancer
por: Gonzalez-Ericsson, Paula I., et al.
Publicado: (2021)

An integrative bioinformatics approach reveals coding and non-coding gene variants associated with gene expression profiles and outcome in breast cancer molecular subtypes
por: Győrffy, Balázs, et al.
Publicado: (2018)

Identification and Validation of a Novel Biologics Target in Triple Negative Breast Cancer
por: Wali, Vikram B., et al.
Publicado: (2019)

Correlation between MRI morphological response patterns and histopathological tumor regression after neoadjuvant endocrine therapy in locally advanced breast cancer: a randomized phase II trial
por: Reis, Joana, et al.
Publicado: (2021)

Adherence to endocrine therapy in early breast cancer in relation to Cytochrome P450 2D6 genotype: a comparison between pharmacy dispensation data and medical records
por: Thorén, Linda, et al.
Publicado: (2023)

Neoadjuvant endocrine therapy use in early stage breast cancer during the covid-19 pandemic
por: Park, Ko Un, et al.
Publicado: (2021)

Comparative efficacy of everolimus plus exemestane versus fulvestrant for hormone-receptor-positive advanced breast cancer following progression/recurrence after endocrine therapy: a network meta-analysis
por: Bachelot, Thomas, et al.
Publicado: (2013)

nextMONARCH Phase 2 randomized clinical trial: overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with endocrine-refractory HR + , HER2– metastatic breast cancer
por: Hamilton, Erika, et al.
Publicado: (2022)

Treatment Sequencing Patterns and Associated Direct Medical Costs of Metastatic Breast Cancer Care in the United States, 2011 to 2021
por: Jaber Chehayeb, Rachel, et al.
Publicado: (2022)

Predictors of Chemosensitivity in Triple Negative Breast Cancer: An Integrated Genomic Analysis
por: Jiang, Tingting, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_t8fceh5clf8q5dhr7ni8gcm5hv